This article is for educational and research purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any peptide.
What Is MOTS-c?
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA Type-c) is a 16-amino acid peptide encoded by the mitochondrial genome — specifically within the 12S rRNA gene. Discovered by Dr. Changhan David Lee's laboratory at the University of Southern California in 2015, MOTS-c was the first mitochondrial-derived peptide (MDP) shown to have systemic metabolic regulatory effects, fundamentally challenging the view that mitochondria are passive energy factories.
MOTS-c represents an emerging class of signaling molecules that establish communication between mitochondria and the nuclear genome (retrograde signaling). It circulates in the blood and acts on distant tissues, functioning essentially as a mitochondrial hormone.
Mechanism of Action
MOTS-c exerts its metabolic effects through several interconnected pathways:
- AMPK activation: MOTS-c activates AMP-activated protein kinase (AMPK), the master cellular energy sensor. AMPK activation triggers a cascade of metabolic effects including increased glucose uptake, enhanced fatty acid oxidation, improved insulin sensitivity, and stimulation of mitochondrial biogenesis. This is the same pathway activated by exercise and metformin.
- Folate cycle regulation: MOTS-c inhibits the methionine-folate cycle, redirecting metabolic flux toward de novo purine synthesis via AICAR accumulation. AICAR is itself an AMPK activator, creating a feedforward metabolic loop.
- Nuclear translocation: Under stress, MOTS-c translocates from the cytoplasm to the nucleus where it interacts with nuclear DNA, regulating gene expression related to stress response and antioxidant defense (including ARE/EpRE pathway activation).
- Skeletal muscle effects: Enhances glucose uptake in skeletal muscle independently of insulin signaling, promoting metabolic flexibility and exercise performance.
Research Findings
Lee et al. (2015) demonstrated that MOTS-c administration prevented age-dependent and high-fat-diet-induced insulin resistance in mice. Treated mice showed improved glucose tolerance, reduced body weight gain, and enhanced insulin sensitivity. A key finding was that MOTS-c levels naturally decline with age and obesity in human plasma, suggesting that declining MOTS-c may contribute to age-related metabolic dysfunction.
Subsequent studies showed MOTS-c improved physical performance in aged mice, functioning as an exercise mimetic that enhanced treadmill endurance capacity. Exercise itself was shown to increase circulating MOTS-c levels in humans — a 2020 study demonstrated that physical exercise induced MOTS-c nuclear translocation in skeletal muscle, suggesting a bidirectional relationship between exercise and MOTS-c signaling.
Population genetics studies have revealed that a MOTS-c polymorphism (m.1382A>C) is enriched in Japanese centenarians and populations from northeast Asia, providing genetic evidence for its role in longevity and metabolic health.
Dosing and Current Status
As a relatively new research peptide, standardized human dosing protocols are not established. Preclinical doses in mouse studies translate to approximately 5-10 mg per day for a human, administered via subcutaneous injection. Human clinical trials are in early stages, and no dosing guidelines have been validated for clinical use. MOTS-c is available as a research peptide but has no regulatory approval for any indication.
The Bottom Line
MOTS-c is a scientifically compelling mitochondrial-derived peptide that bridges the gap between mitochondrial function, metabolic health, and aging. Its AMPK-activating, exercise-mimetic properties and the genetic association with human longevity make it one of the most promising molecules in aging research. However, it is still in the early stages of human translation, with limited clinical data and no established dosing protocols. The research trajectory is promising, but definitive human evidence is still forthcoming.